PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Progressive Age-Associated Blood Brain Barrier Leak/Dysfunction- Nexus of Neurodegenerative Disease Using MRI Markers to Identify Preclinical Disease and Potential New targets for Future Treatments
Version 1
: Received: 20 January 2024 / Approved: 24 January 2024 / Online: 25 January 2024 (15:51:04 CET)
How to cite:
Joseph, C. Progressive Age-Associated Blood Brain Barrier Leak/Dysfunction- Nexus of Neurodegenerative Disease Using MRI Markers to Identify Preclinical Disease and Potential New targets for Future Treatments. Preprints2024, 2024011793. https://doi.org/10.20944/preprints202401.1793.v1
Joseph, C. Progressive Age-Associated Blood Brain Barrier Leak/Dysfunction- Nexus of Neurodegenerative Disease Using MRI Markers to Identify Preclinical Disease and Potential New targets for Future Treatments. Preprints 2024, 2024011793. https://doi.org/10.20944/preprints202401.1793.v1
Joseph, C. Progressive Age-Associated Blood Brain Barrier Leak/Dysfunction- Nexus of Neurodegenerative Disease Using MRI Markers to Identify Preclinical Disease and Potential New targets for Future Treatments. Preprints2024, 2024011793. https://doi.org/10.20944/preprints202401.1793.v1
APA Style
Joseph, C. (2024). Progressive Age-Associated Blood Brain Barrier Leak/Dysfunction- Nexus of Neurodegenerative Disease Using MRI Markers to Identify Preclinical Disease and Potential New targets for Future Treatments. Preprints. https://doi.org/10.20944/preprints202401.1793.v1
Chicago/Turabian Style
Joseph, C. 2024 "Progressive Age-Associated Blood Brain Barrier Leak/Dysfunction- Nexus of Neurodegenerative Disease Using MRI Markers to Identify Preclinical Disease and Potential New targets for Future Treatments" Preprints. https://doi.org/10.20944/preprints202401.1793.v1
Abstract
This review article focuses on the upstream pertinent pathophysiology leading to neurodegenerative disease. Specifically, the nexus appears to be blood brain barrier (BBB) leakiness resulting in a two-prong inflammatory disease spectrum damaging the microvasculature and corrupted protein synthesis and degradation with accumulating misfolded toxic proteins. The suboptimal results of removing misfolded proteins means a new approach to disease in the preclinical state is required aimed at other targets.Validated noninvasive imaging and serologic biomarkers of early preclinical disease implemented in the high-risk patient cohort along with periodic surveillance once effective treatments are developed will be required.This review discusses the physiology and pathophysiology of the BBB, new MRI imaging techniques identifying the leak and altered fluid dynamic effects in the preclinical state. The risk factors for disease development, preventative measures, and potential treatment targets are also discussed.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
